SonoLeukin

**SonoLeukin** is an experimental oncology immunotherapy from Vesselon that combines unmodified interleukin-2 with the company's ultrasound-activated lipid microbubble and liposome delivery platform. The product is described as an IL-2 and Vesselon microbubble complex designed to be activated locally by conventional diagnostic-intensity ultrasound, with the aim of concentrating IL-2 activity in tumor tissue, improving intratumoral biodistribution, and reducing the systemic toxicity that has historically limited IL-2 therapy. Publicly available descriptions indicate that Vesselon has positioned SonoLeukin as a targeted cytokine therapy intended to enhance anti-tumor immune responses and potentially improve checkpoint inhibitor performance in cancers such as recurrent metastatic head and neck cancer and pancreatic cancer. Available sources place the program in preclinical development.

Brand names

SonoLeukin

Other names

IL-2/Vesselon microbubble complex